SecBot SecBot
SECBOTREPLAY Home › Report › TARA

TARA · Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share),…

Protara Therapeutics · PRESS-RELEASE filed Aug 11, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 11, 2026 at 08:00 ET

Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.

  • Q2 2026 net loss of $21.7M ($0.36/share) vs $15.0M ($0.35/share) in Q2 2025
  • Cash and investments of $161.9M as of June 30, 2026, expected to fund operations into 2028
  • Expects to complete enrollment in BCG-Unresponsive cohort of ADVANCED-2 trial in Q4 2026
  • Redesigning ADVANCED-3 trial as multi-cohort exploratory study in broader NMIBC population

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access